At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 27, 2026 at 16:01 ET
Erasca reported highly positive preliminary Phase 1 data for pan-RAS inhibitor ERAS-0015, showing 62% uORR in 2L+ KRAS G12X NSCLC (vs 38% for comparator RMC-6236) and 40% uORR in 2L PDAC (vs 29% comparator), with favorable safety. This is a major catalyst for the stock, potentially positioning ERAS-0015 as best-in-class.
- 62% uORR in 2L+ KRAS G12X NSCLC at PAD 16-32 mg QD vs 38% comparator
- 75% uORR in post-ICI/platinum 2/3L NSCLC at PAD vs 38% comparator
- 40% uORR in 2L KRAS G12X PDAC at PAD vs 29% comparator
- No DLTs, low-grade AEs, no discontinuations due to TRAEs
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access